

Press Release December 7, 2021 Gothenburg, Sweden

## Vitrolife's CEO sells a portion of his shareholding

Vitrolife's CEO Thomas Axelsson has today sold 38,300 shares worth SEK 18.7 million. The remaining number of shares amounts to 13,000 shares.

"The Vitrolife share has developed very positively since I acquired the shares in 2012 and I therefore choose to realize part of the profit for private financial reasons," says Thomas Axelsson, CEO of Vitrolife AB. The transaction will be reported to The Swedish Financial Supervisory Authority (Finansinspektionen) according to current regulations.

Gothenburg, December 7, 2021 VITROLIFE AB (publ) Thomas Axelsson, CEO

## **Contact persons:**

Thomas Axelsson, CEO, tel: +46 31 721 80 01 Mikael Engblom, CFO, tel: +46 31 721 80 14

Vitrolife is an international medical device and genetic services Group. Vitrolife develops, produces and markets products for reproductive health together with services that provide personalised genetic information to improve clinical practices in infertility, women's health and rare diseases. Headquartered in Gothenburg, Sweden, the Group currently employs approximately 1,200 people worldwide. Its products, services and solutions are available in more than 110 markets through a network of subsidiaries and distributors. The Group has a wide-ranging experience in the fertility field with an advanced research capacity. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 90. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 10.50 am CET on December 7, 2021.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails